Latest News

Tuesday, May 03, 2016 | Clinical Trials

AAGP Improves Results in Stem Cells Transplanted in Retina Tissue by 300%

ProtoKinetix has announced that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP has been accepted by the Journal of Tissue Engineering and Regenerative Medicine for publicatio…

Read the full story

Tuesday, May 03, 2016 | Clinical Trials, GrayBug

Graybug Vision Presents Data for Preclinical AMD Treatment Candidate at ARVO 2016

Graybug Vision announced that data from a preclinical study of its lead product, GB-102, a novel injectable depot formulation containing a compound blocking VEGF and PDGF receptors for twice-a-year tr…

Read the full story

Tuesday, May 03, 2016 | Awards, Heidelberg Engineering

Alex Huang, MD, PhD, Receives Heidelberg Engineering’s Research Award 2016

Alex Huang, MD, PhD, is the winner of the Heidelberg Engineering Xtreme Research Award 2016 for his research on aqueous angiography and OCT structural analysis of outflow pathways. He received…

Read the full story

Tuesday, May 03, 2016 | Earnings & Financials, Valeant

Valeant Falls as Buffett Calls Business 'Enormously Flawed'

Valeant Pharmaceuticals International declined as much as 13 percent, the most in a month and a half, after billionaire Warren Buffett criticized the drugmaker’s strategy at the annual meeting o…

Read the full story

Tuesday, May 03, 2016 | Clinical Trials, NovaBay Pharmaceuticals

Clinical Data Presented at ARVO Showing NovaBay’s Avenova Reduces Bacteria on Ocular Skin Surface by More than 90%

NovaBay Pharmaceuticals announced the presentation of clinical data demonstrating that Avenova reduced the bacterial load on the ocular skin surface by more than 90% in 20 minutes without affecting th…

Read the full story

Monday, May 02, 2016 | Medical Studies, Retina, Genentech

Five-Year Outcomes of CATT Study Comparing Anti-VEGF Agents for Treatment of AMD Released

The National Eye Institute’s CATT (Comparison of Age-related Macular Degeneration (AMD) Treatments Trial) study (n=1185) was a 2-year study that compared the relative safety and effectiveness of…

Read the full story

Monday, May 02, 2016 | Grants/Awards

BrightFocus Foundation Honors Five Researchers on Macular Degeneration and Glaucoma

BrightFocus Foundation recognized five scientists in the fields of macular degeneration and glaucoma research, awarding them grants named in honor of leaders in vision research and advocacy. The five …

Read the full story

Monday, May 02, 2016 | Conferences

Call for Abstracts - American Academy of Optometry 2016 Anaheim Scientific Program

The Scientific Program Committee of the American Academy of Optometry invites the submission of abstracts for Academy 2016 Anaheim, to be held Wednesday, November 9 through Saturday, November 12…

Read the full story

Monday, May 02, 2016 | CE Mark Approval, Product Releases, Carl Zeiss Meditec

Zeiss Receives CE Mark Approval for PLEX Elite 9000 Swept-Source OCT

Zeiss announced that it has received CE Mark approval for its new swept-source OCT technology platform, Zeiss PLEX Elite 9000. The new platform expands researchers’ ability to examine the cr…

Read the full story

Monday, May 02, 2016 | Management/Leadership

Tara Moore, PhD, Joins Avellino Labs as R&D Director

Avellino Labs announced that Tara Moore, PhD, has joined the company as R&D Director overseeing all of the company's global research programs, with special emphasis on gene therapy, according …

Read the full story

Monday, May 02, 2016 | Management/Leadership, Valeant

Valeant Guts Board as It Shifts Strategy, Attempts Fresh Start

Valeant Pharmaceuticals International Inc. attempted to put the worst of its problems behind it Friday, announcing a shakeup of its board and filing a long-awaited annual report where it promised sign…

Read the full story

Monday, May 02, 2016 | Clinical Trials

Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease at ARVO

Parion Sciences announced the presentation of a poster containing clinical data for the development stage dry eye treatment P-321. The presentation is a review of the results from a clinical trial of …

Read the full story

Friday, April 29, 2016 | Conferences, Bausch+Lomb

Bausch + Lomb Highlights Scientific and Clinical Research during the Association for Research in Vision and Ophthalmology Annual Meeting in Seattle

Bausch + Lomb announced that eight scientific posters will address the results of a variety of research studies, which feature several of the company’s current product offerings and pipeline pro…

Read the full story

Friday, April 29, 2016 | Conferences, Medical Studies

Femto Trial Results Awaited From Cataract Surgery Meeting

A prospective randomized trial comparing femtosecond laser-assisted cataract surgery with traditional phacoemulsification for eyes with a shallow anterior chamber will be presented at the upcoming Ame…

Read the full story

Friday, April 29, 2016 | Product Releases

Surgical Specialties to Showcase Growing Family of Sharpoint Ophthalmic Instruments at the Upcoming ASCRS Annual Meeting

Surgical Specialties will showcase its growing family of Sharpoint products, including single use surgical instruments, at the upcoming American Society of Cataract and Refractive Surgeons (ASCR…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $16.04  -1.78% 
 Akorn, Inc. $25.28  0.51% 
 Alimera Sciences, Inc. $2.28  1.79% 
 Allergan $217.06  -0.48% 
 Avalanche Biotechnologies $5.53  -2.98% 
 Bayer $113.23  -1.64% 
 Can-Fite Biopharma $2.89  -0.34% 
 Carl Zeiss Meditec $29.34  1.82% 
 Cooper Companies, Inc. $154.34  -0.18% 
 Eleven Biotherapeutics $1.00  28.51% 
 Escalon Medical Corp. $0.77  -4.06% 
 Essilor International $130.00  3.38% 
 Glaukos $19.67  -0.56% 
 Imprimis Pharmaceuticals, Inc. $3.82  -0.65% 
 Inotek Pharmaceuticals $10.33  -0.19% 
 InSite Vision, Inc. $0.35  0.00% 
 IRIDEX Corporation $11.66  -0.29% 
 Johnson & Johnson $112.64  -0.09% 
 Luxottica Group, S.p.A. $56.08  -1.06% 
 Merck & Company, Inc. $55.17  -0.24% 
 NicOx $8.59  -3.27% 
 NovaBay Pharmaceuticals, Inc. $2.55  -5.90% 
 Novartis AG Common Stock $76.19  -0.85% 
 Ocular Therapeutix $11.53  -3.11% 
 Ophthotech Corporation $45.22  -4.45% 
 QLT $1.61  5.23% 
 Quantel $3.55  -1.11% 
 Regeneron $374.29  -2.66% 
 Roche $31.56  -0.93% 
 Second Sight Medical Products $4.51  -2.80% 
 Shire $186.05  0.49% 
 STAAR Surgical Company $7.62  -0.13% 
 TearLab Corporation $0.79  5.63% 
 Thrombogenics $3.70  0.00% 
 Topcon Corporation $9.76  0.00% 
 TriVascular Technologies, Inc. $5.87  0.00% 
 Valeant Pharmaceuticals $34.93  6.99% 
 Xoma $0.79  -2.75%